Medicare funds $30-per-prescription subsidy to long-term care pharmacies

What it does

This bill requires Medicare prescription drug plans to pay long-term care pharmacies an additional $30 per prescription in 2026 (and inflation-adjusted amounts in 2027) when dispensing drugs to certain Medicare beneficiaries. The federal government will fully reimburse plans for these supply fees, so the cost is shifted to taxpayers rather than to insurers or beneficiaries. The bill also mandates a study on whether long-term care pharmacies can remain financially viable in the Medicare system.

Why we flagged it

The operative mechanism is a direct federal subsidy to long-term care pharmacies, funded by full reimbursement of supply fees to Medicare plans. The public-health framing (preserving access) wraps a straightforward payment to a private sector.

What the text implies

• The $30 fee is paid 'in addition to' existing reimbursements (ingredient costs, dispensing fees), meaning it is a pure add-on with no offset or efficiency requirement.
• Full federal reimbursement to plans means the subsidy cost is invisible to insurers and beneficiaries—only taxpayers bear it, reducing political pressure to justify the expense.
• The bill sunsets after 2027, creating a cliff; pharmacies may lobby for renewal, establishing a precedent for sector-specific subsidies.
• No performance metrics, outcome measures, or access guarantees are tied to the subsidy—payment is automatic per prescription regardless of whether access actually improves.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Beneficiaries in long-term care settings may retain access to specialized pharmacies (a concrete public benefit), but the cost is borne entirely by taxpayers through increased Medicare spending with no offsetting savings or efficiency gains identified. The bill is a targeted subsidy to a specific pharmacy sector rather than a broad public health measure.

Who stands to gain

• long-term care pharmacies
• pharmacy benefit managers (if they operate long-term care divisions)

Named in the bill

Medicare Part D, PDP sponsors, MA organizations, long-term care pharmacies, Secretary of Health and Human Services, Comptroller General, National Uniform Claim Committee

Where it stands

46 cosponsors: 32 Republicans, 14 Democrats.

• Aug 22, 2025 — Introduced · Congress.gov: “Introduced in House”
• Aug 22, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

15 lobbying clients named this bill on 23 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,830,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

Beth Van Duyne, the sponsor, reported $1,221,522 in PAC receipts in the 2026 cycle. $5,500 of that came from 1 PAC tied to these lobbying clients.

• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• Cardinal Health Inc — $460,000 on 1 filing
• Senior Care Pharmacy Coalition — $320,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing
• Senior Care Pharmacy Coalition — $180,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.